199 related articles for article (PubMed ID: 28601493)
1. Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients.
Ren Y; Li X; Wang W; He W; Wang J; Wang Y
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):415-423. PubMed ID: 28601493
[TBL] [Abstract][Full Text] [Related]
2. The role of circulating miRNAs in multiple myeloma.
Zhang J; Xiao X; Liu J
Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
[TBL] [Abstract][Full Text] [Related]
3. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
Hao M; Zang M; Wendlandt E; Xu Y; An G; Gong D; Li F; Qi F; Zhang Y; Yang Y; Zhan F; Qiu L
Int J Cancer; 2015 Apr; 136(8):1835-44. PubMed ID: 25220540
[TBL] [Abstract][Full Text] [Related]
4. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
5. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis.
Hao M; Zang M; Zhao L; Deng S; Xu Y; Qi F; An G; Qin Y; Sui W; Li F; Yang W; Li Z; Yi S; Zou D; Zhan F; Qiu L
Oncotarget; 2016 Apr; 7(15):19589-600. PubMed ID: 26995755
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.
Gupta N; Kumar R; Seth T; Garg B; Sati HC; Sharma A
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1601-1611. PubMed ID: 30891618
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma.
Shen X; Ye Y; Qi J; Shi W; Wu X; Ni H; Cong H; Ju S
Clin Chem Lab Med; 2017 May; 55(5):748-754. PubMed ID: 27155004
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
10. Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma.
Zhang ZY; Li YC; Geng CY; Wang HJ; Chen WM
Biomed Res Int; 2019; 2019():1575468. PubMed ID: 31915680
[TBL] [Abstract][Full Text] [Related]
11. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
12. [Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma].
Xu YN; Xiao CR; Huang YD; Lu QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):471-475. PubMed ID: 28446295
[TBL] [Abstract][Full Text] [Related]
13. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray.
Yyusnita ; Norsiah ; Zakiah I; Chang KM; Purushotaman VS; Zubaidah Z; Jamal R
Malays J Pathol; 2012 Dec; 34(2):133-43. PubMed ID: 23424776
[TBL] [Abstract][Full Text] [Related]
15. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
16. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
17. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.
Seckinger A; Meißner T; Moreaux J; Benes V; Hillengass J; Castoldi M; Zimmermann J; Ho AD; Jauch A; Goldschmidt H; Klein B; Hose D
Oncotarget; 2015 Nov; 6(36):39165-83. PubMed ID: 26472281
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
19. The potential of miRNAs as biomarkers for multiple myeloma.
Rocci A; Hofmeister CC; Pichiorri F
Expert Rev Mol Diagn; 2014 Nov; 14(8):947-59. PubMed ID: 25098410
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients.
Yang YL; Xu LP; Zhuo FL; Wang TY
Tumour Biol; 2015 Sep; 36(9):7069-75. PubMed ID: 25869877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
